Abstract
Mice were given a saline preinjection and habituation to the testing environment followed by injection of amphetamine (0.675–5.0 mg/kg IP) and apomorphine (AP, 15–80 μg/kg SC) 15 min later. AP produced a dose-dependent inhibition of the amphetamine-induced locomotor activity. A dose of 40 μg/kg AP increased approximately threefold the amphetamine dose required to induce the same increase in activity. Repeated administration of AP (30 mg/kg IP once daily for 14 days) resulted in an enhanced response (in the early portion of the time response) to amphetamine challenge, while the ability of subsequent microgram challenge doses of AP to reduce the response were unaffected. Similarly, repeated administration (twice-daily IP injections for 5 days) of amphetamine (5.0 mg/kg) resulted in an enhanced locomotor response to amphetamine challenge and no change in the ability of AP to inhibit the response. These results suggest that repeated administrations of dopamine agonists, although acting through different mechanisms (i.e., indirect versus direct), increase the initial release of neurotransmitter. However, the repeated administration of these agonists does not attenuate the ability of AP to inhibit the release of the neurotransmitter induced by amphetamine. The regulatory functions (i.e., presynaptic receptor control) of release appears to remain intact, but the level of neuronal activity has been increased.
Similar content being viewed by others
References
Bailey RC, Jackson DM (1978) A pharmacological study of changes in central nervous system receptor responsiveness after long-term dexamphetamine and apomorphine administration. Psychopharmacology 56:317–326
Carlsson A, Persson T, Roos BE, Walinder J (1972) Potentiation of phenothiazines by α-methyltyrosine in treatment of chronic schizophrenia. J Neural Transm 33:83–90
Carlsson A, Kehr W, Lindquist M (1974) Short-term control of tyrosine hydroxylase. In: Usdin E (ed) Neuropsychopharmacology of monoamines and their regulatory enzymes. Raven, New Yerk, pp 135–142
Carlsson A (1975) Receptor-mediated control of dopamine metabolism In: Usdin E, Bunney WE Jr (eds) Pre- and post-synaptic receptors. Marcel-Dekker, New York, pp 49–65
Carlsson A, Kehr W, Lindquist M (1976) The role of intraneuronal amine levels in the feedback control of dopamine, noradrenaline and 5-hydroxytryptamine synthesis in rat brain. J Neural Transm 39:1–19
Carlsson A (1976) Some aspects of dopamine in the basal ganglia. In: Yahr MD (ed) The basal ganglia. Raven, New York, pp 181–189
Carlsson A, Kehr W, Lindquist M (1977) Agonist-antagonist interaction on dopamine receptors in brain, as reflected in the rates of tyrosine and tryptophan hydroxylation. J Neural Transm 40:99–113
Carlsson A (1978b) Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135:164–173
Carlsson A (1978b) Does dopamine have a role in schizophrenia. Biol Psychiatry 13:3–21
Gale K (1980) Effects of chronic neuroleptic treatment on tyrosine hydroxylase in dopaminergic terminals: Comparisons between drugs and brain regions reveal different mechanisms of tolerance. Adv Biochem Pharmacol 24:23–29
Kehr W, Carlsson A, Lindquist M, Magnusson T, Atack C (1972) Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol 24:744
Kelly PH, Seviour PW, Iversen SD (1975) Amphetamine and apomorphine responses in the rate following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 93:507–522
Klawans RE, Margolin DI (1975) Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Arch Gen Psychiatry 32:725–732
Langer SZ (1974) Presynaptic regulation of catecholamine release. Biochem Pharmacol 23:1793–1800
Langer SZ (1981) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32:337–362
Riffee WH, Wilcox RE, Smith RV (1979) Modification of drug-induced behavioral arousal by preinjection routines in mice. Psychopharmacology 63:1–5
Riffee WH, Wilcox RE, Vaughn DM, Smith RV (1982) Dopamine receptor sensitivity after chronic dopamine agonists: Striatal 3H-spiroperidol binding in mice after chronic administration of high doses of apomorphine, N-n-propylnorapomorphine and dextroamphetamine. Psychopharmacology 77:146–149
Smith RV, Wilcox RE, Soine WH, Riffee WH, Baldessarini RJ, Kula NS (1979) Plasma levels of apomorphine following intravenous, intraperitoneal and oral administration to mice and rats. Res Commun Chem Pathol Pharmacol 24:483–499
Smith RV, Klein AE, Wilcox RE, Riffee WH (1981) Bioavailability of apomorhine in the mouse and comparison to the time course of stereotyped cage-climbing. Pharm Sci 70:1144–1147
Vaughn DM, Wilcox RE (1982) Chronic apomorphine administration increases basal in vivo striatal dopamine turnover and produces opposite effects on turnover after apomorphine and spiroperidol challenge. Pharmacologist 24:105
Wilcox RE, Hightower WH, Smith RV (1979) Post-hoc data analysis in biomedical research. Amer Lab 11:32–45
Wilcox RE, Riffee WH, Chen PC, Hammett III, S, Smith RV (1980) Behavioral facilitation following chronic administration of N-n-propylnorapomorphine. Psychopharmacology 72:113–115
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Riffee, W.H., Wilcox, R.E. Effects of multiple pretreatment with apomorphine and amphetamine on amphetamine-induced locomotor activity and its inhibition by apomorphine. Psychopharmacology 85, 97–101 (1985). https://doi.org/10.1007/BF00427330
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00427330